SynthesisBioMed research international2018
Irreversible Electroporation in Patients with Pancreatic Cancer: How Important Is the New Weapon?
Synthesis in BioMed research international, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 20 citations in OpenAlex.
- Thermal side effects during pulsed field ablation: an analysis using computer modelling.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2025Article
- Proactive esophageal cooling during radiofrequency cardiac ablation: data update including applications in very high-power short duration ablation.Expert review of medical devices · 2025Review
- Mechanisms of action behind the protective effects of proactive esophageal cooling during radiofrequency catheter ablation in the left atrium.Heart rhythm O2 · 2024Review
- Endoscopic Ultrasound-Guided Laser Ablation Using a Diffusing Applicator for Locally Advanced Pancreatic Cancer Treatment.Cancers · 2022Article
- Locoregional therapies and their effects on the tumoral microenvironment of pancreatic ductal adenocarcinoma.World journal of gastroenterology · 2022Review
- [Ablative treatment options for locally advanced unresectable and borderline resectable pancreatic carcinoma].Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPancreatic cancer (PC) is a deadly disease with poor prognosis in the general population. We aimed to quantitate overall survival of patients with PC after irreversible electroporation (IRE) and the incidence of relevant complications.
methodsWe performed a literature search via five electronic databases (PubMed, Embase, Web of Science, Scopus, and Cochrane Library databases) up to August 2017. The primary outcomes were overall survival and prognosis. Secondary outcomes included the response of post-IRE complications. Fixed-effects or random-effects meta-analysis was conducted to pool these data.
resultsA total of 15 eligible articles involving 535 patients were included. The primary outcomes showed that the pooled prevalence estimates of overall survival were 94.1% (95% CI: 90.7-97.5), 80.9% (95% CI: 72.5-89.4), 54.5% (95% CI: 38.3-70.6), and 33.8% (95% CI: 14.2-53.5) at 3, 6, 12, and 24 months, and the pooled prevalence data of complete response (CR) at 2 months, partial response (PR) at 3 months, and progression at 3 months were 12.5% (95% CI: 2.9-22.2), 48.5% (95% CI: 39.4-57.6), and 19.7% (95% CI: 7.3-32.2), respectively. The secondary outcomes showed that the pooled prevalence values of post-IRE complications were abscess 6.6% (95% CI: 0.2-13), fistula 10.6% (95% CI: 2.5-18.7), pain 33.5% (95% CI: 14.5-52.5), infection 16.1% (95% CI: 3.9-28.4), thrombosis 4.9% (95% CI: 1.2-8.5), pancreatitis 7.2% (95% CI: 3.1-11.2), bleeding 4.2% (95% CI: -0.5-8.9), cholangitis 4.2% (95% CI: -0.5-8.9), nausea 9.6% (95% CI: 4.4-14.8), biliary obstruction 13.8% (95% CI: 4.2-23.3), chest tightness 7.6% (95% CI: 0.5-14.6), and hypoglycemia 5.9% (95% CI: -0.4-12.2).
conclusionsThis meta-analysis indicated a clear survival benefit for PC patients who received irreversible electroporation therapy, although future safety and effectivity monitoring from more large-scale studies will be needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.